Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System

Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide. The aim of this s...

Full description

Saved in:
Bibliographic Details
Published inDiabetes, metabolic syndrome and obesity Vol. 13; pp. 2433 - 2442
Main Authors Monda, Vincenzo, Sessa, Francesco, Ruberto, Maria, Carotenuto, Marco, Marsala, Gabriella, Monda, Marcellino, Cambria, Maria Teresa, Astuto, Marinella, Distefano, Alfio, Messina, Giovanni
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2020
Dove
Dove Medical Press
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide. The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects. Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min). The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported. The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise.
AbstractList Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide. The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects. Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min). The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported. The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise.
Vincenzo Monda,1 Francesco Sessa,2 Maria Ruberto,3 Marco Carotenuto,4 Gabriella Marsala,5 Marcellino Monda,1 Maria Teresa Cambria,6 Marinella Astuto,7 Alfio Distefano,6 Giovanni Messina2 1Department of Experimental Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Caserta 81100, Italy; 2Department of Clinical and Experimental Medicine, University of Foggia, Foggia 71121, Italy; 3CDR Santa Maria del Pozzo, Naples 80049, Italy; 4Clinic of Child and Adolescent Neuropsychiatry, Department of Mental Health, Physical and Preventive Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Caserta 81100, Italy; 5Struttura Complessa di Farmacia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Foggia, Foggia 71121, Italy; 6Section of Medical Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania 95123, Italy; 7Azienda Ospedaliera "Policlinico Vittorio Emanuele", U.O. di Anestesia e Terapia Intensiva, Catania 95123, ItalyCorrespondence: Francesco SessaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia 71122, ItalyTel +39 0881 736926Email francesco.sessa@unifg.itBackground: Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.Aim: The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30- 34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.Methods: Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120- 140 bpm for 45 min).Results: The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.Conclusion: The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise.Keywords: metabolic syndrome, MetS, Orexin A, body mass index, BMI, heart rate, HR, cholesterol, physical activity
Background: Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide. Aim: The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects. Methods: Ten male subjects (aged 54 [+ or -] 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 [+ or -] 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min). Results: The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported. Conclusion: The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise. Keywords: metabolic syndrome, MetS, Orexin A, body mass index, BMI, heart rate, HR, cholesterol, physical activity
Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.BACKGROUNDAerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.AIMThe aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min).METHODSTen male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min).The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.RESULTSThe results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise.CONCLUSIONThe results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise.
Audience Academic
Author Monda, Marcellino
Astuto, Marinella
Ruberto, Maria
Sessa, Francesco
Distefano, Alfio
Monda, Vincenzo
Carotenuto, Marco
Marsala, Gabriella
Cambria, Maria Teresa
Messina, Giovanni
Author_xml – sequence: 1
  givenname: Vincenzo
  surname: Monda
  fullname: Monda, Vincenzo
– sequence: 2
  givenname: Francesco
  orcidid: 0000-0003-0357-8791
  surname: Sessa
  fullname: Sessa, Francesco
– sequence: 3
  givenname: Maria
  surname: Ruberto
  fullname: Ruberto, Maria
– sequence: 4
  givenname: Marco
  orcidid: 0000-0002-8136-7597
  surname: Carotenuto
  fullname: Carotenuto, Marco
– sequence: 5
  givenname: Gabriella
  orcidid: 0000-0003-0981-4134
  surname: Marsala
  fullname: Marsala, Gabriella
– sequence: 6
  givenname: Marcellino
  surname: Monda
  fullname: Monda, Marcellino
– sequence: 7
  givenname: Maria Teresa
  surname: Cambria
  fullname: Cambria, Maria Teresa
– sequence: 8
  givenname: Marinella
  orcidid: 0000-0002-9365-1309
  surname: Astuto
  fullname: Astuto, Marinella
– sequence: 9
  givenname: Alfio
  surname: Distefano
  fullname: Distefano, Alfio
– sequence: 10
  givenname: Giovanni
  surname: Messina
  fullname: Messina, Giovanni
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32753926$$D View this record in MEDLINE/PubMed
BookMark eNptkt1r2zAUxc3oWLuub3sehsHYw5JZX5bdh0Houq3QUli614lr6TpRsa1MUkr7309u0pGMSg8SV79zuJLO6-xgcANm2VtSTCnh8vPXq_n1dE6FLCv5IjsiRFYTWRTyYGd_mJ2EcFuMQxac0lfZIaNSsJqWR9nvGXrXWJ2f36PXNmAOg8mvMELjulSePwzGux5P85sl5j9dh7lrU7VfQVxiTMRMR3tn48OjMI4QGnefkBCxf5O9bKELeLJdj7Nf385vzn5MLq-_X5zNLie6JDxOGCGNLIhk2jBREKC1bpigRpZatJqZGiSShBquGQNRCl0LrJG1Ak1jsGHH2cXG1zi4VStve_APyoFVjwXnFwp86rZDVZFaQsWhYqzigpY1QFlVQIgGUzW8Sl5fNl6rddOj0ThED92e6f7JYJdq4e6UZILXhCeDj1sD7_6sMUTV26Cx62BAtw6KclaU6cP4iL7foAtIrdmhdclRj7ialYzWRXoUkajpM1SaBnurUyJam-p7gg87giVCF5fBdeto3RD2wXe7d_13yaeAJIBuAO1dCB5bpW2E0Se1YDtFCjUGUY1BVNsgJtGn_0RPvs_ifwHghNvw
CitedBy_id crossref_primary_10_1002_wsbm_1536
crossref_primary_10_1016_j_celrep_2022_111497
crossref_primary_10_3390_ijerph19095145
crossref_primary_10_1097_MD_0000000000034206
crossref_primary_10_1097_YIC_0000000000000552
crossref_primary_10_3390_nu17061095
crossref_primary_10_1007_s40519_022_01434_2
crossref_primary_10_1016_j_yfrne_2022_100993
crossref_primary_10_3390_metabo10110455
crossref_primary_10_7759_cureus_34009
crossref_primary_10_3390_ijms251910742
crossref_primary_10_1016_j_bbr_2023_114791
Cites_doi 10.3390/antiox8120643
10.2165/00007256-200636040-00004
10.3389/fphys.2018.00261
10.1161/01.CIR.0000075572.40158.77
10.3389/fphys.2017.00773
10.1155/2016/3565127
10.1152/ajpregu.1999.277.6.R1780
10.1152/physrev.00018.2001
10.1113/expphysiol.2009.050526
10.1016/j.jshs.2016.04.001
10.1046/j.1365-2362.2003.01227.x
10.1016/j.nbd.2014.08.025
10.1155/2014/943162
10.1515/jbcpp-2015-0133
10.1016/j.autneu.2012.05.003
10.6064/2012/205027
10.18632/oncotarget.24729
10.1111/j.1467-789X.2012.00992.x
10.1097/AUD.0000000000000305
10.3389/fneur.2017.00188
10.1152/ajpregu.00208.2003
10.3389/fphys.2018.00259
10.3389/fphys.2017.00085
10.1016/j.mehy.2008.12.037
10.3727/105221617X15124844266408
10.1146/annurev.arplant.55.031903.141701
10.1371/journal.pone.0032361
10.1161/CIRCULATIONAHA.108.191394
10.1152/ajpheart.00703.2016
10.1111/obr.12229
10.1016/j.cbi.2017.12.024
10.1016/0026-0495(94)90277-1
10.1089/ars.2011.3976
10.1155/2016/7239639
10.18632/aging.101386
10.1155/2017/3831972
10.1007/s00424-002-0918-6
10.1124/pr.109.001321
10.1155/2014/131024
10.1007/s12035-017-0865-z
10.1249/MSS.0000000000001122
10.1242/dmm.001180
10.1016/j.jnutbio.2015.08.024
10.1164/rccm.201204-0596PP
10.1007/s40519-014-0107-6
10.1161/01.CIR.0000111245.75752.C6
10.1016/j.bbadis.2013.06.007
10.1007/s11332-018-0464-z
10.1098/rsfs.2014.0040
10.2741/4736
10.3389/fphys.2018.00982
10.1016/j.molmet.2015.07.003
10.1016/j.numecd.2006.07.005
ContentType Journal Article
Copyright 2020 Monda et al.
COPYRIGHT 2020 Dove Medical Press Limited
2020 Monda et al. 2020 Monda et al.
Copyright_xml – notice: 2020 Monda et al.
– notice: COPYRIGHT 2020 Dove Medical Press Limited
– notice: 2020 Monda et al. 2020 Monda et al.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.2147/DMSO.S257687
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed


MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Monda et al
EISSN 1178-7007
EndPage 2442
ExternalDocumentID oai_doaj_org_article_8197a84a833845269aa688a11cad8b48
PMC7354914
A632900175
32753926
10_2147_DMSO_S257687
Genre Journal Article
GroupedDBID ---
0YH
29F
2WC
53G
5VS
7RV
8C1
8FI
8FJ
8G5
AAYXX
ABUWG
ACGFO
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BKEYQ
BPHCQ
BVXVI
C1A
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
EBS
EJD
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
M2O
M48
M~E
NAPCQ
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TDBHL
TR2
UKHRP
VDV
NPM
PMFND
7X8
PJZUB
PPXIY
5PM
PUEGO
ID FETCH-LOGICAL-c614t-311b70173cd3501a29cb352d76c5fc3d9a7e1c61d4c33a565c95e9e3f5edbdeb3
IEDL.DBID M48
ISSN 1178-7007
IngestDate Wed Aug 27 01:31:28 EDT 2025
Thu Aug 21 14:11:05 EDT 2025
Tue Aug 05 10:39:21 EDT 2025
Tue Jun 17 20:58:10 EDT 2025
Tue Jun 10 20:42:57 EDT 2025
Thu May 22 21:04:51 EDT 2025
Thu Jan 02 22:54:36 EST 2025
Tue Jul 01 01:45:16 EDT 2025
Thu Apr 24 22:59:42 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords metabolic syndrome
heart rate
MetS
Orexin A
body mass index
cholesterol
HR
BMI
physical activity
Language English
License http://creativecommons.org/licenses/by-nc/3.0
2020 Monda et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c614t-311b70173cd3501a29cb352d76c5fc3d9a7e1c61d4c33a565c95e9e3f5edbdeb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9365-1309
0000-0003-0357-8791
0000-0002-8136-7597
0000-0003-0981-4134
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/DMSO.S257687
PMID 32753926
PQID 2430668744
PQPubID 23479
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_8197a84a833845269aa688a11cad8b48
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7354914
proquest_miscellaneous_2430668744
gale_infotracmisc_A632900175
gale_infotracacademiconefile_A632900175
gale_healthsolutions_A632900175
pubmed_primary_32753926
crossref_citationtrail_10_2147_DMSO_S257687
crossref_primary_10_2147_DMSO_S257687
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-01-01
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – month: 01
  year: 2020
  text: 2020-01-01
  day: 01
PublicationDecade 2020
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
PublicationTitle Diabetes, metabolic syndrome and obesity
PublicationTitleAlternate Diabetes Metab Syndr Obes
PublicationYear 2020
Publisher Dove Medical Press Limited
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Dove
– name: Dove Medical Press
References Holvoet (ref28) 2012; 2012
Radák (ref57) 2002; 445
Sessa (ref12) 2018; 10
Davalli (ref17) 2016; 2016
Silverman (ref30) 2014; 4
Apel (ref58) 2004; 55
Monda (ref20) 2017; 8
Sperandeo (ref48) 2018; 34
Van Der Windt (ref11) 2018; 18
Chieffi (ref7) 2017; 8
Perez-Leighton (ref45) 2014; 1842
Sessa (ref6) 2018; 14
Williams (ref49) 1994; 43
Grundy (ref37) 2006
Monda (ref24) 2017; 2017
O’Neill (ref38) 2015; 16
Finaud (ref62) 2006; 36
Vestbo (ref52) 2013; 187
Rizzo (ref61) 2016; 7
Kaur (ref2) 2014; 2014
Cazzola (ref60) 2003; 33
Monda (ref53) 2014; 2014
Sallam (ref54) 2016; 2016
Dongiovanni (ref51) 2016; 29
Monda (ref43) 2019; 33
Salerno (ref47) 2019; 24
Simioni (ref16) 2018; 9
Hart (ref27) 2017; 312
Couillard (ref50) 2007
ref34
Polito (ref46) 2018; 9
ref33
Messina (ref18) 2018; 9
Monda (ref25) 2018; 55
Marra (ref23) 2017; 33
Shirasaka (ref26) 1999; 277
Powers (ref19) 2010; 95
Navarro (ref56) 2004; 286
Obici (ref5) 2015; 4
Jackson (ref59) 2011; 15
Chieffi (ref36) 2017; 8
Normandin (ref9) 2017; 49
Tsujino (ref44) 2009; 61
Huang (ref32) 2014; 72
Messina (ref13) 2012; 169
Donini (ref10) 2014; 19
Mackersie (ref31) 2016; 37
Byrne (ref4) 2018; 362
Wiklund (ref8) 2016; 5
Phull (ref15) 2018; 281
Huang (ref3) 2009; 2
Messina (ref22) 2016; 27
Messina (ref42) 2018; 9
Grundy (ref1) 2004; 109
Ritchie (ref39) 2007; 17
Li (ref55) 2009; 72
Messina (ref21) 2017; 33
Chaput (ref29) 2012; 13
Valenzano (ref35) 2019; 8
Thompson (ref40) 2003; 107
Steinberger (ref41) 2009; 119
Dröge (ref14) 2002; 82
References_xml – volume: 8
  start-page: 643
  year: 2019
  ident: ref35
  publication-title: Antioxidants
  doi: 10.3390/antiox8120643
– volume: 36
  start-page: 327
  year: 2006
  ident: ref62
  publication-title: Sports Med
  doi: 10.2165/00007256-200636040-00004
– volume: 9
  year: 2018
  ident: ref42
  publication-title: Front Physiol
  doi: 10.3389/fphys.2018.00261
– volume: 107
  start-page: 3109
  year: 2003
  ident: ref40
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000075572.40158.77
– volume: 8
  year: 2017
  ident: ref20
  publication-title: Front Physiol
  doi: 10.3389/fphys.2017.00773
– volume: 33
  start-page: 645
  year: 2017
  ident: ref21
  publication-title: Acta Medica Mediterr
– volume: 2016
  start-page: 1
  year: 2016
  ident: ref17
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2016/3565127
– volume: 362
  year: 2018
  ident: ref4
  publication-title: BMJ
– volume: 277
  start-page: R1780
  year: 1999
  ident: ref26
  publication-title: Am J Physiol Regul Integr Comp Physiol
  doi: 10.1152/ajpregu.1999.277.6.R1780
– volume: 82
  start-page: 47
  year: 2002
  ident: ref14
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00018.2001
– volume: 95
  start-page: 1
  year: 2010
  ident: ref19
  publication-title: Exp Physiol
  doi: 10.1113/expphysiol.2009.050526
– volume: 33
  start-page: 587
  year: 2019
  ident: ref43
  publication-title: J Biol Regul Homeost Agents
– volume: 5
  start-page: 151
  year: 2016
  ident: ref8
  publication-title: J Sport Health Sci
  doi: 10.1016/j.jshs.2016.04.001
– volume: 33
  start-page: 924
  year: 2003
  ident: ref60
  publication-title: Eur J Clin Invest
  doi: 10.1046/j.1365-2362.2003.01227.x
– volume: 72
  start-page: 3
  year: 2014
  ident: ref32
  publication-title: Neurobiol Dis
  doi: 10.1016/j.nbd.2014.08.025
– volume: 2014
  start-page: 1
  year: 2014
  ident: ref2
  publication-title: Cardiol Res Pract
  doi: 10.1155/2014/943162
– volume: 27
  start-page: 611
  year: 2016
  ident: ref22
  publication-title: J Basic Clin Physiol Pharmacol
  doi: 10.1515/jbcpp-2015-0133
– volume: 169
  start-page: 102
  year: 2012
  ident: ref13
  publication-title: Auton Neurosci Basic Clin
  doi: 10.1016/j.autneu.2012.05.003
– ident: ref34
– volume: 2012
  start-page: 1
  year: 2012
  ident: ref28
  publication-title: Scientifica (Cairo)
  doi: 10.6064/2012/205027
– volume: 9
  start-page: 17181
  year: 2018
  ident: ref16
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.24729
– volume: 13
  start-page: 681
  year: 2012
  ident: ref29
  publication-title: Obes Rev
  doi: 10.1111/j.1467-789X.2012.00992.x
– volume: 37
  start-page: 118S
  year: 2016
  ident: ref31
  publication-title: Ear Hear
  doi: 10.1097/AUD.0000000000000305
– volume: 8
  year: 2017
  ident: ref7
  publication-title: Front Neurol
  doi: 10.3389/fneur.2017.00188
– volume: 286
  start-page: R505
  year: 2004
  ident: ref56
  publication-title: Am J Physiol Integr Comp Physiol
  doi: 10.1152/ajpregu.00208.2003
– volume: 9
  year: 2018
  ident: ref18
  publication-title: Front Physiol
  doi: 10.3389/fphys.2018.00259
– volume: 8
  year: 2017
  ident: ref36
  publication-title: Front Physiol
  doi: 10.3389/fphys.2017.00085
– year: 2007
  ident: ref50
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 72
  start-page: 527
  year: 2009
  ident: ref55
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2008.12.037
– volume: 18
  start-page: 89
  year: 2018
  ident: ref11
  publication-title: Gene Expr
  doi: 10.3727/105221617X15124844266408
– ident: ref33
– volume: 55
  start-page: 373
  year: 2004
  ident: ref58
  publication-title: Annu Rev Plant Biol
  doi: 10.1146/annurev.arplant.55.031903.141701
– volume: 7
  start-page: e32361
  year: 2016
  ident: ref61
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0032361
– volume: 119
  start-page: 628
  year: 2009
  ident: ref41
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.108.191394
– volume: 312
  start-page: H1031
  year: 2017
  ident: ref27
  publication-title: Am J Physiol Heart Circ Physiol
  doi: 10.1152/ajpheart.00703.2016
– volume: 16
  start-page: 1
  year: 2015
  ident: ref38
  publication-title: Obes Rev
  doi: 10.1111/obr.12229
– volume: 281
  start-page: 121
  year: 2018
  ident: ref15
  publication-title: Chem Biol Interact
  doi: 10.1016/j.cbi.2017.12.024
– volume: 33
  start-page: 1225
  year: 2017
  ident: ref23
  publication-title: Acta Medica Mediterr
– volume: 43
  start-page: 917
  year: 1994
  ident: ref49
  publication-title: Metabolism
  doi: 10.1016/0026-0495(94)90277-1
– volume: 15
  start-page: 2477
  year: 2011
  ident: ref59
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2011.3976
– volume: 2016
  start-page: 1
  year: 2016
  ident: ref54
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2016/7239639
– volume: 10
  start-page: 166
  year: 2018
  ident: ref12
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.101386
– volume: 2017
  start-page: 1
  year: 2017
  ident: ref24
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2017/3831972
– volume: 445
  start-page: 273
  year: 2002
  ident: ref57
  publication-title: Pflugers Arch
  doi: 10.1007/s00424-002-0918-6
– volume: 61
  start-page: 162
  year: 2009
  ident: ref44
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.109.001321
– year: 2006
  ident: ref37
  publication-title: Curr Opin Cardiol
– volume: 2014
  year: 2014
  ident: ref53
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2014/131024
– volume: 55
  start-page: 1
  year: 2018
  ident: ref25
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-017-0865-z
– volume: 49
  start-page: 413
  year: 2017
  ident: ref9
  publication-title: Med Sci Sports Exerc
  doi: 10.1249/MSS.0000000000001122
– volume: 2
  start-page: 231
  year: 2009
  ident: ref3
  publication-title: Dis Model Mech
  doi: 10.1242/dmm.001180
– volume: 29
  start-page: 1
  year: 2016
  ident: ref51
  publication-title: J Nutr Biochem
  doi: 10.1016/j.jnutbio.2015.08.024
– volume: 187
  start-page: 347
  year: 2013
  ident: ref52
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201204-0596PP
– volume: 19
  start-page: 249
  year: 2014
  ident: ref10
  publication-title: Eat Weight Disord
  doi: 10.1007/s40519-014-0107-6
– volume: 34
  start-page: 349
  year: 2018
  ident: ref48
  publication-title: Acta Medica Mediterr
– volume: 109
  start-page: 433
  year: 2004
  ident: ref1
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000111245.75752.C6
– volume: 1842
  start-page: 440
  year: 2014
  ident: ref45
  publication-title: Biochim Biophys Acta Mol Basis Dis
  doi: 10.1016/j.bbadis.2013.06.007
– volume: 14
  start-page: 705
  year: 2018
  ident: ref6
  publication-title: Sport Sci Health
  doi: 10.1007/s11332-018-0464-z
– volume: 4
  start-page: 20140040
  year: 2014
  ident: ref30
  publication-title: Interface Focus
  doi: 10.1098/rsfs.2014.0040
– volume: 24
  start-page: 564
  year: 2019
  ident: ref47
  publication-title: Front Biosci
  doi: 10.2741/4736
– volume: 9
  year: 2018
  ident: ref46
  publication-title: Front Physiol
  doi: 10.3389/fphys.2018.00982
– volume: 4
  start-page: 692
  year: 2015
  ident: ref5
  publication-title: Mol Metab
  doi: 10.1016/j.molmet.2015.07.003
– volume: 17
  start-page: 319
  year: 2007
  ident: ref39
  publication-title: Nutr Metab Cardiovasc Dis
  doi: 10.1016/j.numecd.2006.07.005
SSID ssj0000070422
Score 2.268805
Snippet Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic...
Background: Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with...
Vincenzo Monda,1 Francesco Sessa,2 Maria Ruberto,3 Marco Carotenuto,4 Gabriella Marsala,5 Marcellino Monda,1 Maria Teresa Cambria,6 Marinella Astuto,7 Alfio...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2433
SubjectTerms Analysis
body mass index (bmi)
cholesterol
Exercise
Heart rate
heart rate (hr)
Medical research
metabolic syndrome (mets)
orexin a
Original Research
physical activity
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3faxQxEA7SB_FF_O1qrREUH2Tt7Sa7SXy71pYinIJnoU-GbDJLhetu6W3BP9-ZZHvcIuJLHzeZhWQyk5nZTb6PsbdNFXQwrcjbEEG1QeYGdJsT0ItsvZ8l4PnF1_rkVH45q862qL7oTFiCB06K28eIpZyWTmMtFemwnau1dkXhXdCNjNd8MeZtFVMp8VUEbpWYVXSu8Dmdeidanv1wse4_rmOqrSbxKML2_705b0Wn6cnJrVB0_IDdH3NIPk9jf8juQPeI3V2Mf8kfs59zIHQlz49GPiXuusAXMOCCr7B5OaIUfOJoJPx7vwLet9h6QfTEdKmRz30ilYgvDiQEof_NE7z5E3Z6fPTj8CQfeRRyj8F3wG22aBR6nvCBfiO60vgG866gal-1XgTjFBQoGqQXwmGG500FBkRbQWgCVttP2U7Xd_Cc8Vnta5hBBR4UYdEbXcngTA1BQNClz9iHG21aP4KME9fFymKxQbq3nxfLb3aZdJ-xdxvpywSu8Q-5A1qYjQxBYscGNBQ7Gor9n6Fk7DUtq033SzeObee1KA0F6ypj76MEuTYO2rvxhgJOnUCyJpK7E0l0ST_pfnNjOpa66BxbB_312pYSS7SaKAcy9iyZ0mZWosTS0ZR1xtTEyCbTnvZ0v84jIrgSWOYX8sVt6Oklu1fSN4X4mWmX7QxX1_AKE6-h2Ys-9gcg1Sh0
  priority: 102
  providerName: Directory of Open Access Journals
Title Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System
URI https://www.ncbi.nlm.nih.gov/pubmed/32753926
https://www.proquest.com/docview/2430668744
https://pubmed.ncbi.nlm.nih.gov/PMC7354914
https://doaj.org/article/8197a84a833845269aa688a11cad8b48
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9QwEB_uA8QX8dvquVZQfJCe2yZtUkFk79zzEPaUWxf26UqapCrstbrbg_O_dybpLldO8aXQZFqaZKYzk4_fD-BFmRpp8opFlXGg2pZHuZVVREAvvNJ66IHnJyfZ8Yx_mqfzLVizjXYduPprakd8UrPlYv_y1-_3aPDvaBtzzMUbc75q9lcuchbbsIs-SRCXwaQL9H0gLAjsyjOtyEjgvd8Ff-0FPf_kYPyv_6yveKv-TsorrunoNtzqYspw5JXgDmzZ-i7cmHSr5vfgbGQJbUmH445fKVS1CSe2RQVYYPG0Qy14G6LShKfNwoZNhaXnRFdMhxzDkfYkE-7BloSsaS5DD3d-H2ZH46-Hx1HHqxBpdMYt_nbjUqAlMm1oWVEluS4xDjMi02mlmcmVsDGKGq4ZUxjx6Ty1uWVVak1pMPt-ADt1U9tHEA4zndmhTa22grDpc5lyo_LMGmaNTHQAr9e9WegOdJy4LxYFJh_U98WHyfRzMfV9H8DLjfRPD7bxD7kDGpiNDEFku4Jm-a3oLK7AUEcoyZXEJNzxqCuVSaniWCsjSy4DeEbDWvjzphtDL0YZS3Jy3mkAr5wEKR9-tFbdiQVsOoFm9ST3epJoorpX_XytOgVV0b622jYXqyLhmLJlREEQwEOvSptWsQRTyTzJAhA9Jes1u19T__juEMIFw7Q_5o__28QncDOhCQQ3p7QHO-3ywj7FKKstB7AtD-MB7B6MT76cDtxcBV4_zrGMTOsPwwgpOQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aerobic+Exercise+and+Metabolic+Syndrome%3A+The+Role+of+Sympathetic+Activity+and+the+Redox+System&rft.jtitle=Diabetes%2C+metabolic+syndrome+and+obesity&rft.au=Distefano%2C+Alfio&rft.au=Carotenuto%2C+Marco&rft.au=Cambria%2C+Maria+Teresa&rft.au=Astuto%2C+Marinella&rft.date=2020-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-7007&rft.eissn=1178-7007&rft.volume=13&rft.spage=2433&rft_id=info:doi/10.2147%2Fdmso.s257687&rft.externalDBID=n%2Fa&rft.externalDocID=A632900175
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7007&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7007&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7007&client=summon